Viral Immunology, published by Mary Ann Liebert, Inc, stands as a prominent journal dedicated to advancing the understanding of the interplay between viral infections and host immune responses. With a strong focus on immunology, molecular medicine, and virology, the journal provides a platform for the dissemination of high-quality research findings and innovative methodologies that could shape the future of these critical fields. Although it currently holds a Q3 rating across its relevant categories and a respectable ranking within the Scopus database, Viral Immunology continues to strive for excellence with a commitment to publishing influential research that informs both academic and clinical practices. The journal accepts submissions in various formats—original research, reviews, and commentaries—catering to a diverse readership that includes researchers, professionals, and students engaged in the biological and medical sciences. Readers can anticipate insightful articles that address urgent challenges in immunological responses to viral infections, paving the way for new therapeutic strategies and public health initiatives.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

Current Opinion in Virology, published by Elsevier Science Ltd, is a premier journal dedicated to advancing knowledge in the dynamic field of virology. Established as a respected source of comprehensive reviews and critical evaluations, this journal boasts an impressive impact factor and has achieved a distinguished Q1 category ranking for virology, signifying its pivotal role in the academic community. Serving researchers, professionals, and students alike, Current Opinion in Virology presents insightful contributions that delve into the latest developments, emerging trends, and pivotal challenges facing virology today. With its Scopus ranking placing it in the top 15% of its field, the journal provides unparalleled access to cutting-edge research that informs both basic and applied aspects of virology. Although not an open-access journal, it offers options for subscriptions that ensure accessibility to critical content. As the field continuously evolves, Current Opinion in Virology remains at the forefront, bridging the gap between research and clinical application, making it an essential resource for all in the virology community.

VIRUS GENES is an esteemed journal published by Springer, dedicated to advancing our understanding of virology and its related fields, including genetics, molecular biology, and immunology. With a publication history that spans from 1987 to 2024, this journal provides researchers and professionals with a platform to disseminate high-quality, peer-reviewed articles that explore the intricacies of viral genetics and their implications in health and disease. With an impact factor placing it in the Q3 quartile across multiple categories in 2023, including Genetics and Virology, VIRUS GENES serves as a crucial resource for academics seeking to stay at the forefront of viral research. Its commitment to showcasing innovative research makes it an invaluable asset for students and professionals aiming to deepen their knowledge in the rapidly evolving landscape of virology. Although currently not offering Open Access, the journal ensures wide accessibility through institutional subscriptions, thereby playing a vital role in the collaboration between scientists globally.

Virology Journal, published by BMC, stands as a prominent open-access platform since 2004, dedicated to advancing the field of virology and infectious diseases. With its E-ISSN: 1743-422X, this journal is based in the United Kingdom and strives to disseminate high-quality research that enhances our understanding of viral pathogens and their interactions with hosts. Recognized with a Q1 classification in the category of Infectious Diseases and a Q2 in Virology for 2023, Virology Journal holds significant standing in the academic community, ranking #82/344 in Medicine - Infectious Diseases and #26/80 in Immunology and Microbiology - Virology. Its commitment to open access ensures that cutting-edge research is freely available to researchers, professionals, and students worldwide, fostering collaboration and innovation in the fight against viral diseases. The journal aims to publish original research articles, reviews, and commentaries that will stimulate discourse and spark new ideas within the virology community.

The JOURNAL OF GENERAL VIROLOGY, published by the Microbiology Society, is a premier academic journal dedicated to advancing the field of virology. Established in 1967, this influential journal covers a wide spectrum of research from basic virology to applied studies, serving as a vital resource for researchers, professionals, and students alike. With its ISSN 0022-1317 and E-ISSN 1465-2099, the journal is recognized for its rigorous peer-review process and high-quality publications, attaining a commendable Q2 ranking in the Virology category for 2023. The journal's focus on disseminating innovative findings and fostering critical discussions contributes significantly to the understanding of viral mechanisms, disease processes, and potential therapeutic strategies. Although it does not currently offer Open Access options, the journal remains accessible to the academic community, with a strong commitment to supporting virology research globally. As part of Scopus' top-tier rankings, illustrating its impact within the category of Immunology and Microbiology, the JOURNAL OF GENERAL VIROLOGY continues to play a pivotal role in shaping the future of virological science.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

VIRUS RESEARCH is a leading journal dedicated to the field of virology, published by Elsevier, and has been a cornerstone for researchers, professionals, and students since its inception in 1984. With an impressive impact factor, the journal is highly regarded, holding a Q2 category ranking in both Cancer Research and Infectious Diseases, as well as in Virology for 2023. Based in the Netherlands, it publishes high-quality, peer-reviewed articles that explore the intricate relationships between viruses and their hosts, novel therapeutic strategies, and advancements in virus biology. Researchers will find that it ranks 49th in Medicine - Infectious Diseases and 19th in Immunology and Microbiology - Virology according to Scopus, signifying its significant contribution and relevance in the academic world. VIRUS RESEARCH facilitates a platform for sharing groundbreaking discoveries, forming a vital part of the global scientific community, making it an essential read for those involved in the study of viral pathogens and their implications in medicine and biochemistry.

Tumour Virus Research, an esteemed journal published by Elsevier, serves as a vital resource in the fields of cancer research, infectious diseases, and virology. With an impact factor reflective of its influence and recognized as a Q2 journal in multiple categories as of 2023, it rigorously presents high-impact research dedicated to the understanding of viral pathogens in tumorigenesis. Since its transition to an Open Access model in 2021, the journal has enhanced accessibility, empowering researchers and the academic community globally to explore cutting-edge findings. The journal covers a broad scope, encompassing the intricate interactions between viruses and cancer biology, which is crucial for developing novel therapeutic strategies. With a commitment to advancing scientific knowledge, Tumour Virus Research welcomes submissions that push the boundaries of current understanding and contribute to the ongoing battle against virus-mediated cancers, making it an indispensable publication for professionals, researchers, and students in the field.

ACTA VIROLOGICA, a key journal in the field of virology and infectious diseases, is published by FRONTIERS MEDIA SA in Slovakia, serving the global scientific community with groundbreaking research since its inception in 1957. This esteemed journal, identified by ISSN 0001-723X and E-ISSN 1336-2305, provides a platform for rigorous peer-reviewed articles that contribute significantly to our understanding of viral pathogens and their implications in medicine. Positioned within the Q3 category for both Infectious Diseases and Miscellaneous Medicine, and a Q4 category for Virology in 2023, ACTA VIROLOGICA offers crucial insights into the evolving landscape of virology research. With its robust accessibility options, this journal appeals to a diverse readership, including researchers, healthcare professionals, and students, fostering a collaborative environment to advance the field of virology. The editorial objective is to enhance the catalog of knowledge pertaining to viruses, promoting innovative approaches in prevention, diagnostics, and treatment. Located at AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE CH-1015, SWITZERLAND, ACTA VIROLOGICA continues to be a vital resource in the collective efforts to combat viral disease challenges.